Category ""
ADVERTISING
This new technology applied to TAC (Envarsus® or LCP-TAC) has achieved 4 main objectives: (1) improved bioavailability, (2) reduced dose fractioning to one tablet per day, (3) limited variability concentrations of TAC, and (4) lower doses of TAC will be administered.
This retrospective, observational 24-month study investigated the tolerability of once-daily MeltDose® prolonged-release tacrolimus (LCPT) after switching from twice-daily immediate-release tacrolimus (IR-Tac) in a real-world cohort of 150 patients with previous liver transplantation.
MeltDose technology, a platform developed by Veloxis Pharmaceuticals A/S (Hørsholm, Denmark), is a drug delivery technology used to enhance the oral bioavailability and control the release of a drug, especially low water-soluble or insoluble drugs.
A hallmark differentiation between this formulation and other once- and twice-daily tacrolimus products is the proprietary MeltDose drug delivery technology which is designed to improve the bioavailability of drugs with low water solubility.
This new tacrolimus formulation uses ‘Meltdose’ technology to achieve this goal. LCP Meltdose technology works by decreasing the particle size of the drug to the molecular scale thus increasing particle surface area.
proinvestor.com DownloadWhether you are looking to develop new formulations or to improve the eficacy of existing ones, MeltDose® technology gives you a cost-effective way to deliver innovative products that will help improve the quality of life for patients.
This new technology applied to TAC (Envarsus or LCP-TAC) has achieved 4 main objectives: (1) improved bioavailability, (2) reduced dose fractioning to one tablet per day, (3) limited variability concentrations of TAC, and (4) lower doses of TAC will be administered.
MeltDose® technology, a platform developed by Veloxis Pharmaceuticals A/S (Hørsholm, Denmark), a company founded in 2002, is a drug delivery technology used to enhance the oral bioavailability and control the release of a drug, especially low water-soluble or -insoluble drugs.
MeltDose® TAC (LCP- TAC) is a novel formulation resulting in increased dissolution and better absorption. However, scanty evidence is available on safety of LCP-TAC in de novo LT with regard to neurologic toxicity. This study aimed to evaluate the safety of LCP-TAC compared to twice-daily (TD- TAC).
Background: An extended-release formulation of tacrolimus designed for once-daily administration (LCP-TAC) is a new prolonged-release tacrolimus (TAC-PR) formulation using a drug delivery technology designed to enhance the bioavailability of drugs compared with TAC-PR.